Diagnosing M. bovis, however, has remained a stubborn bottleneck. Traditional microbiological culture is definitive but labor-intensive and may require days to weeks because of the fastidious growth requirements of the organism, a turnaround time fundamentally incompatible with outbreak decision-making. Serologic assays deliver faster results but often cannot reliably distinguish active infection from past exposure or maternal antibody. Nucleic acid amplification tests such as quantitative polymerase chain reaction have therefore become the gold standard thanks to their high analytical sensitivity and specificity, yet PCR-based methods are tethered to centralized laboratories, requiring sophisticated thermal cycling infrastructure and trained personnel. For the bison industry, where repeated animal handling for resampling is stressful and can pose substantial safety risks, the need for a rapid chute-side diagnostic that delivers actionable results during a single handling event has been especially acute.

To close this gap, researchers have now engineered and validated a diagnostic assay that synergistically couples recombinase polymerase amplification with CRISPR-Cas12a detection, achieving the low-copy analytical sensitivity of gold-standard qPCR while operating entirely under isothermal conditions. The work, published in MicrobiologyOpen, targets the uvrC gene, a conserved housekeeping marker widely used for molecular identification of M. bovis. Although uvrC is broadly conserved among Mycoplasma species, species-specific sequence polymorphisms within the selected target region permit differentiation of M. bovis from closely related species, and the gene is highly conserved among M. bovis isolates, making it a preferred species-specific qPCR target for routine diagnostic detection in cattle.

The technical logic of the platform rests on two complementary molecular engines. Recombinase polymerase amplification, unlike PCR, operates at a constant low temperature of 37 to 42 degrees Celsius and can tolerate inhibitors commonly present in clinical matrices such as nasal swabs and lung tissue extracts. Standalone isothermal assays, however, often suffer from non-specific amplification, producing false positives when coupled with non-specific detection methods like intercalating dyes. The Type V effector Cas12a resolves this by adding an additional layer of sequence specificity. Upon binding a target DNA sequence complementary to its guide RNA, Cas12a is activated and non-specifically cleaves nearby single-stranded DNA reporters, generating a fluorescence signal only when the intended amplicon is present in the appropriate PAM-dependent context.

Optimization began with the amplification step. A 558-base-pair region of the uvrC gene was PCR-amplified from M. bovis genomic DNA extracted from lung tissue of a PCR-confirmed infected bison with gross pulmonary lesions, then cloned into a plasmid vector to serve as the standard DNA control. Eight primer-pair combinations targeting fragments of roughly 100 to 400 base pairs were evaluated in RPA reactions incubated at 39 degrees Celsius for 20 minutes. Most primer pairs yielded distinct bands at the expected sizes, and primer pair PP7 was selected for all subsequent optimization and validation because it demonstrated robust and specific amplification and provided suitable target sites for the design of three distinct guide RNAs within the amplified region.

The CRISPR effector step was then tuned with equal care. Three guide RNAs were designed to target distinct sites within the amplified uvrC region, each adjacent to a 5′-TTTG-3′ protospacer-adjacent motif and selected for low sequence homology to other Mycoplasma species. All three guides enabled Cas12a-mediated detection of the plasmid standard, producing a green fluorescence signal within 30 to 60 minutes, with gRNA3 producing the fastest and most intense response. The single-stranded DNA fluorophore-quencher reporter concentration was optimized to balance time-to-threshold, signal intensity, and background fluorescence; while maximal fluorescence was reached at 5 micromolar, higher reporter concentrations also increased background in negative controls, and 0.75 micromolar provided the best visual readout with minimal background. Cas12a protein titration indicated best fluorescence intensity at 50 nanomolar.

A central finding of the work is the requirement for RPA pre-amplification to achieve clinically relevant detection limits. When M. bovis genomic DNA from three PCR-confirmed positive samples was tested directly in the CRISPR-Cas12a reaction, no fluorescence signal was detected with any of the guide RNAs, whereas the plasmid standard produced bright fluorescence. After the same genomic DNA samples were first subjected to RPA amplification, positive fluorescence signals were obtained, peaking at approximately 20 to 25 minutes before plateauing. Benchmarking against qPCR on serial dilutions of the plasmid standard made the sensitivity gap stark: qPCR reliably detected as few as roughly 8 copies, direct Cas12a detection without pre-amplification produced no measurable fluorescence at any copy number, and RPA-coupled detection recovered robust fluorescence across the dilution series, including at the 8-copy level. In mass units, direct Cas12a interrogation generated visible fluorescence only between 700 and 7 nanograms of the standard, with no signal below 7 nanograms even after 60 minutes.

Clinical validation across 110 samples demonstrated complete diagnostic performance. All 50 M. bovis PCR-positive clinical samples from bison and cattle, spanning lung tissue, milk, nasal swabs, and nasopharyngeal swabs, were positive by the RPA-CRISPR-Cas12a assay. All 13 M. canis-positive samples from dogs and all 10 M. felis-positive samples from cats were negative, confirming the absence of cross-reactivity with closely related species. Among 37 samples positive by PCR for Mycoplasma species that had not initially been speciated, three were positive by the M. bovis assay and were subsequently confirmed as M. bovis by species-specific qPCR. Overall, the assay showed 100 percent sensitivity, 100 percent specificity, and 100 percent concordance with reference PCR-qPCR, with exact 95 percent confidence intervals of 93.3 to 100 percent for sensitivity and 93.7 to 100 percent for specificity. M. bovis-positive samples carried PCR Ct values ranging from approximately 15 to 38, and all were detected following RPA pre-amplification, with fluorescence intensity showing an inverse association with Ct values, Spearman’s rho of negative 0.575, hinting at semi-quantitative potential for bacterial load estimation.

The dual-guide strategy emerged as a particularly interesting kinetic trade-off. While some reports suggest that multiplexing guides leads to additive signal intensity, the researchers observed lower peak fluorescence but faster time-to-threshold with the dual-guide complex. This likely reflects competing dynamics: multiple guides increase the probability of rapid initial target capture, reducing the lag phase, but they compete for the available Cas12a pool, slightly dampening the maximum trans-cleavage velocity per target molecule. For diagnostic purposes, the accelerated onset of the signal is more valuable than absolute peak height, as it potentially allows shorter incubation times, and requiring recognition by two guides imposes higher stringency, reducing the likelihood of off-target activation by closely related Mycoplasma species. The gRNA2 plus gRNA3 combination was therefore adopted as the optimal balance of signal strength and assay complexity.

Before the platform can become a true pen-side tool, several adaptations remain. The current workflow relies on a two-step transfer of RPA product into the Cas12a mix, which introduces a risk of amplicon contamination in high-throughput environments, and developing a one-pot formulation remains challenging due to the competing buffer and temperature requirements of the enzymes. The assay still requires DNA extraction and cold-chain storage for protein-based reagents, and the guide RNAs were not challenged against non-mycoplasmal agents associated with bovine respiratory disease complex such as Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. Matrix tolerance to inhibitors in minimally processed antemortem samples was not directly evaluated, since all testing used purified DNA extracts identical to those used for reference PCR. Future iterations should focus on non-invasive sampling methods such as deep nasopharyngeal swabs or transtracheal washes, lyophilized reagents, and a transition from fluorescence to a visual lateral flow readout, in which a biotin-FAM labeled reporter is cleaved upon Cas12a activation and the released FAM molecule binds anti-FAM antibodies at a test line, producing a visible band. With these developments, the study lays a foundational framework for rapid, instrument-free, on-site diagnostics that could facilitate early intervention and improved herd health management in resource-limited agricultural settings.

Subject of Research: Development and clinical validation of an RPA-CRISPR-Cas12a isothermal assay for sensitive detection of Mycoplasma bovis

Article Title: Synergistic Integration of Recombinase Polymerase Amplification and CRISPR–Cas12a Enables High‐Sensitivity Detection of Mycoplasma bovis

Article References: Yaghoubi, D., & V. Pillai, V. (2026). Synergistic Integration of Recombinase Polymerase Amplification and CRISPR–Cas12a Enables High‐Sensitivity Detection of Mycoplasma bovis. MicrobiologyOpen, 15(5), Article e70435. https://doi.org/10.1002/mbo3.70435

Image Credits: AI Generated

DOI: 10.1002/mbo3.70435

Keywords: Mycoplasma bovis, CRISPR-Cas12a, recombinase polymerase amplification, isothermal amplification, bovine respiratory disease, point-of-care diagnostics, uvrC gene, qPCR, cattle, bison, lateral flow assay, molecular surveillance